目次

Table of Contents

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS & REGIONS COVERED
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Primary research objectives
2.1.2.2 Key data from primary sources
2.1.2.3 Key industry insights
2.1.2.4 Breakdown of primary interviews
2.2 MARKET SIZE ESTIMATION
2.2.1 SUPPLY-SIDE ANALYSIS (REVENUE SHARE ANALYSIS)
2.2.2 COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS
2.2.3 TOP-DOWN APPROACH: SUPPLY-SIDE ANALYSIS
2.3 DATA TRIANGULATION AND MARKET BREAKDOWN
2.4 MARKET SHARE ESTIMATION
2.5 STUDY ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.6.1 METHODOLOGY-RELATED LIMITATIONS
2.6.2 SCOPE-RELATED LIMITATIONS
2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 RESPIRATORY DIAGNOSTICS MARKET OVERVIEW
4.2 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET,
BY PRODUCT & SERVICE AND COUNTRY (2023)
4.3 RESPIRATORY DIAGNOSTICS MARKET: REGIONAL MIX
4.4 RESPIRATORY DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing incidence of respiratory disorders
5.2.1.2 Expanding geriatric population and rise in sedentary lifestyles
5.2.1.3 Growing awareness about respiratory health
5.2.1.4 Advancements in diagnostic technologies
5.2.2 RESTRAINTS
5.2.2.1 High cost of diagnostic tests
5.2.2.2 Limited reimbursements
5.2.2.3 Shortage of skilled professionals
5.2.3 OPPORTUNITIES
5.2.3.1 High growth potential of emerging economies
5.2.3.2 Increasing demand for POC testing
5.2.3.3 Growing awareness about untreated OSA
5.2.4 CHALLENGES
5.2.4.1 Complexities associated with diagnosis of viral respiratory infections
5.2.4.2 Limited access to peripheral lung lesions in bronchoscopy
5.3 INDUSTRY TRENDS
5.3.1 POINT-OF-CARE TESTING
5.3.2 PERSONALIZED MEDICINE
5.4 TECHNOLOGY ANALYSIS
5.4.1 KEY TECHNOLOGIES
5.4.1.1 Home-based & personal DHTs
5.4.1.2 PFT tools and molecular & imaging diagnostics
5.4.2 COMPLEMENTARY TECHNOLOGIES
5.4.2.1 AI-enhanced imaging
5.4.2.2 Serological & telehealth platforms
5.4.3 ADJACENT TECHNOLOGIES
5.4.3.1 Rapid respiratory diagnostic tests
5.5 PORTER’S FIVE FORCES ANALYSIS
5.5.1 THREAT OF NEW ENTRANTS
5.5.2 THREAT OF SUBSTITUTES
5.5.3 BARGAINING POWER OF SUPPLIERS
5.5.4 BARGAINING POWER OF BUYERS
5.5.5 INTENSITY OF COMPETITIVE RIVALRY
5.6 REGULATORY ANALYSIS
5.6.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.6.2 REGULATORY LANDSCAPE
5.6.2.1 North America
5.6.2.1.1 US
5.6.2.1.2 Canada
5.6.2.2 Europe
5.6.2.3 Asia Pacific
5.6.2.3.1 India
5.6.2.3.2 China
5.6.2.3.3 Japan
5.6.2.4 Latin America
5.6.2.5 Middle East & Africa
5.7 PATENT ANALYSIS
5.7.1 KEY PATENTS GRANTED
5.8 TRADE ANALYSIS
5.8.1 IMPORT DATA FOR HS CODE 901819
5.8.2 EXPORT DATA FOR HS CODE 901819
5.9 PRICING ANALYSIS
5.9.1 AVERAGE SELLING PRICE OF RESPIRATORY DIAGNOSTIC PRODUCTS,
BY KEY PLAYER (2024)
5.9.2 AVERAGE SELLING PRICE TREND OF RESPIRATORY DIAGNOSTIC PRODUCTS,
BY REGION, 2021-2023
5.10 VALUE CHAIN ANALYSIS
5.11 KEY STAKEHOLDERS & BUYING CRITERIA
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.11.2 KEY BUYING CRITERIA
5.12 KEY CONFERENCES & EVENTS, 2024-2025
5.13 UNMET NEEDS/END-USER EXPECTATIONS
5.14 ADJACENT MARKET ANALYSIS
5.15 ECOSYSTEM ANALYSIS
5.16 CASE STUDY ANALYSIS
5.17 SUPPLY CHAIN ANALYSIS
5.18 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.19 INVESTMENT & FUNDING SCENARIO
5.20 REIMBURSEMENT SCENARIO
5.21 IMPACT OF AI/GENERATIVE AI ON RESPIRATORY DIAGNOSTICS MARKET

6 RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE
6.1 INTRODUCTION
6.2 INSTRUMENTS & DEVICES
6.2.1 INTRODUCTION OF AUTOMATED & HIGH-THROUGHPUT INSTRUMENTS
TO DRIVE MARKET
6.3 ASSAYS & REAGENTS
6.3.1 INCREASING DEMAND FOR RESPIRATORY DIAGNOSTIC TEST KITS TO PROPEL MARKET
6.4 SERVICES & SOFTWARE
6.4.1 INCREASING DEMAND FOR CONSISTENT UPGRADES AND SUPPORT SERVICES TO FUEL MARKET

7 RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE
7.1 INTRODUCTION
7.2 MECHANICAL TESTS
7.2.1 PULMONARY FUNCTION TESTS
7.2.1.1 Spirometry
7.2.1.1.1 Diagnosis of COPD and pulmonary fibrosis to drive market
7.2.1.2 Peak flow tests
7.2.1.2.1 Ability to provide accurate lung function monitoring with non-invasiveness benefits to fuel uptake
7.2.1.3 Other pulmonary function tests
7.2.2 OBSTRUCTIVE SLEEP APNEA DIAGNOSTIC TESTS
7.2.2.1 Large presence of untreated population to drive market
7.2.3 OTHER MECHANICAL TESTS
7.3 IMAGING TESTS
7.3.1 X-RAY
7.3.1.1 Integration of AI into X-ray devices for enhanced imaging capabilities
to drive market
7.3.2 COMPUTED TOMOGRAPHY
7.3.2.1 Rising focus on obtaining high-resolution CT images to boost demand
7.3.3 MAGNETIC RESONANCE IMAGING (MRI)
7.3.3.1 Ability to provide detailed lung images without radiation exposure
to drive market
7.3.4 POSITRON EMISSION TOMOGRAPHY (PET)
7.3.4.1 Growing focus on detection & monitoring of treatment response to lung cancer to drive market
7.3.5 OTHER IMAGING TESTS
7.4 TRADITIONAL DIAGNOSTIC TESTS
7.4.1 IMMUNODIAGNOSTICS
7.4.1.1 Rising demand for rapid disease diagnosis to fuel uptake
7.4.2 BIOCHEMICAL TESTS
7.4.2.1 Ability to accurately measure biomarkers in pneumonia and
bronchitis infections to boost demand
7.4.3 MICROSCOPY
7.4.3.1 Inadequate sensitivity towards emerging viruses to restrain market
7.5 MOLECULAR DIAGNOSTIC TESTS
7.5.1 POLYMERASE CHAIN REACTION (PCR)
7.5.1.1 Development of portable and real-time PCR machines to drive market
7.5.2 NUCLEIC ACID AMPLIFICATION TEST (NAAT)
7.5.2.1 Rapid identification of viral, bacterial, and fungal infections to fuel demand
7.5.3 IN SITU HYBRIDIZATION (ISH)
7.5.3.1 Utilization of probes for pathogen detection to support market growth
7.5.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING (NGS)
7.5.4.1 High-throughput capabilities for rapid analysis of genetic data
to propel market
7.5.5 MICROARRAYS
7.5.5.1 Detection of hepatitis C and respiratory viruses to support market growth
7.5.6 OTHER MOLECULAR DIAGNOSTIC TESTS

8 RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE
8.1 INTRODUCTION
8.2 TUBERCULOSIS
8.2.1 FAVORABLE FUNDING INITIATIVES FOR TB TREATMENT TO DRIVE MARKET
8.3 ASTHMA
8.3.1 INCREASING AIR POLLUTION AND GROWING USE OF TOBACCO-BASED PRODUCTS TO DRIVE MARKET
8.4 LUNG CANCER
8.4.1 NON-SMALL-CELL LUNG CANCER (NSCLC)
8.4.1.1 Rising investments in advanced radiographic technologies to fuel market
8.4.2 SMALL-CELL LUNG CANCER (SCLC)
8.4.2.1 Growing emphasis on precision testing to drive market
8.4.3 OTHER LUNG CANCERS
8.5 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
8.5.1 ADVANCEMENTS IN SPIROMETRY AND PLETHYSMOGRAPHY FOR
COPD DIAGNOSIS TO FUEL MARKET
8.6 PNEUMONIA
8.6.1 RISING INCIDENCE OF RESPIRATORY INFECTIONS TO BOOST DEMAND
8.7 OTHER DISEASES

9 RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE
9.1 INTRODUCTION
9.2 SYNDROMIC DIAGNOSIS
9.2.1 DETECTION OF MULTIPLE PANELS OF VIRAL PATHOGENS TO PROPEL MARKET
9.3 ETIOLOGICAL DIAGNOSIS
9.3.1 IDENTIFICATION OF SPECIFIC CAUSE OF RESPIRATORY ILLNESSES TO FUEL MARKET
9.4 PROGNOSIS DIAGNOSIS
9.4.1 ASSESSMENT OF BIOMARKERS FOR DISEASE PROGRESSION TO SUPPORT MARKET GROWTH
?

10 RESPIRATORY DIAGNOSTICS MARKET, BY END USER
10.1 INTRODUCTION
10.2 HOSPITALS & CLINICS
10.2.1 GROWING ACCESSIBILITY TO ADVANCED EQUIPMENT TO FUEL MARKET
10.3 DIAGNOSTIC LABORATORIES
10.3.1 ABILITY TO PROVIDE AFFORDABLE TESTING PROCESSES WITH TIMELY RESULTS
TO BOOST DEMAND
10.4 LONG-TERM CARE & SPECIALTY CENTERS
10.4.1 PROVISION OF SPECIALIZED & ADVANCED SERVICES TO PROPEL MARKET
10.5 ACADEMIC & RESEARCH INSTITUTES
10.5.1 FAVORABLE FUNDING INITIATIVES TO SUPPORT MARKET GROWTH

11 RESPIRATORY DIAGNOSTICS MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
11.2.2 US
11.2.2.1 Growing accessibility to technologically advanced products
to boost demand
11.2.3 CANADA
11.2.3.1 Rising incidence of COPD to drive market
11.3 EUROPE
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
11.3.2 GERMANY
11.3.2.1 Increasing public healthcare expenditure to foster market growth
11.3.3 UK
11.3.3.1 Rising establishment of hospitals and increasing number of surgical procedures to fuel market
11.3.4 FRANCE
11.3.4.1 High prevalence of smoking and increasing demand for respiratory
devices to drive market
11.3.5 ITALY
11.3.5.1 Unfavorable amendments to healthcare policies to restrain market
11.3.6 SPAIN
11.3.6.1 Increasing demand for home healthcare services to support market growth
11.3.7 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
11.4.2 JAPAN
11.4.2.1 Availability of universal healthcare reimbursement policy to drive market
11.4.3 CHINA
11.4.3.1 High incidence of viral respiratory infections to propel market
11.4.4 INDIA
11.4.4.1 Expansion of leading medical device manufacturers and large target
patient population to drive market
11.4.5 AUSTRALIA
11.4.5.1 High prevalence of chronic lung diseases to boost demand
11.4.6 SOUTH KOREA
11.4.6.1 Expanding geriatric population and rising incidence of chronic
respiratory conditions to fuel market
11.4.7 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
11.5.2 BRAZIL
11.5.2.1 Favorable government initiatives for healthcare sector improvement
to drive market
11.5.3 MEXICO
11.5.3.1 Rising prevalence of obesity & hypertension to fuel uptake
11.5.4 REST OF LATIN AMERICA
11.6 MIDDLE EAST & AFRICA
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
11.6.2 GCC COUNTRIES
11.6.2.1 Kingdom of Saudi Arabia (KSA)
11.6.2.1.1 Investments in advanced healthcare technologies to drive market
11.6.2.2 United Arab Emirates (UAE)
11.6.2.2.1 Rising prevalence of asthma to support market growth
11.6.2.3 Other GCC Countries
11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE
12.1 INTRODUCTION
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, JANUARY 2021-DECEMBER 2024
12.3 REVENUE ANALYSIS, 2019-2023
12.4 MARKET SHARE ANALYSIS, 2023
12.4.1 RANKING OF KEY MARKET PLAYERS
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
12.5.5.1 Company footprint
12.5.5.2 Region footprint
12.5.5.3 Product & service footprint
12.5.5.4 Test type footprint
12.5.5.5 Disease type footprint
12.5.5.6 End-user footprint
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
12.7 BRAND/PRODUCT COMPARISON
12.8 R&D EXPENDITURE OF KEY PLAYERS
12.9 COMPANY VALUATION & FINANCIAL METRICS
12.9.1 FINANCIAL METRICS
12.9.2 COMPANY VALUATION
12.10 COMPETITIVE SCENARIO
12.10.1 PRODUCT & SERVICE LAUNCHES AND APPROVALS
12.10.2 DEALS
12.10.3 EXPANSIONS
12.10.4 OTHER DEVELOPMENTS

13 COMPANY PROFILES
13.1 KEY PLAYERS
13.1.1 KONINKLIJKE PHILIPS N.V.
13.1.1.1 Business overview
13.1.1.2 Products & services offered
13.1.1.3 Recent developments
13.1.1.3.1 Product launches
13.1.1.3.2 Deals
13.1.1.3.3 Expansions
13.1.1.4 MnM view
13.1.1.4.1 Key strengths
13.1.1.4.2 Strategic choices
13.1.1.4.3 Weaknesses & competitive threats
13.1.2 BECTON, DICKINSON AND COMPANY
13.1.2.1 Business overview
13.1.2.2 Products & services offered
13.1.2.3 Recent developments
13.1.2.3.1 Product launches & approvals
13.1.2.3.2 Deals
13.1.2.4 MnM view
13.1.2.4.1 Key strengths
13.1.2.4.2 Strategic choices
13.1.2.4.3 Weaknesses & competitive threats
13.1.3 ABBOTT LABORATORIES
13.1.3.1 Business overview
13.1.3.2 Products & services offered
13.1.3.3 Recent developments
13.1.3.3.1 Product approvals
13.1.3.4 MnM view
13.1.3.4.1 Key strengths
13.1.3.4.2 Strategic choices
13.1.3.4.3 Weaknesses & competitive threats
13.1.4 THERMO FISHER SCIENTIFIC INC.
13.1.4.1 Business overview
13.1.4.2 Products & services offered
13.1.4.3 Recent developments
13.1.4.3.1 Product & service launches
13.1.4.3.2 Deals
13.1.4.4 MnM view
13.1.4.4.1 Key strengths
13.1.4.4.2 Strategic choices
13.1.4.4.3 Weaknesses & competitive threats
13.1.5 GE HEALTHCARE TECHNOLOGIES, INC.
13.1.5.1 Business overview
13.1.5.2 Products & services offered
13.1.5.3 Recent developments
13.1.5.3.1 Product & service launches & approvals
13.1.5.3.2 Deals
13.1.5.3.3 Other developments
13.1.5.4 MnM view
13.1.5.4.1 Key strengths
13.1.5.4.2 Strategic choices
13.1.5.4.3 Weaknesses & competitive threats
13.1.6 BIO-RAD LABORATORIES, INC.
13.1.6.1 Business overview
13.1.6.2 Products & services offered
13.1.6.3 Recent developments
13.1.6.3.1 Product launches & approvals
13.1.6.3.2 Deals
13.1.7 BIOMÉRIEUX
13.1.7.1 Business overview
13.1.7.2 Products & services offered
13.1.7.3 Recent developments
13.1.7.3.1 Product launches & approvals
13.1.7.3.2 Deals
13.1.8 REVVITY, INC.
13.1.8.1 Business overview
13.1.8.2 Products & services offered
13.1.8.3 Recent developments
13.1.8.3.1 Product launches & approvals
13.1.8.3.2 Deals
13.1.9 SEEGENE INC.
13.1.9.1 Business overview
13.1.9.2 Products & services offered
13.1.9.3 Recent developments
13.1.9.3.1 Product launches & approvals
13.1.9.3.2 Deals
13.1.9.3.3 Expansions
13.1.9.3.4 Other developments
13.1.10 NIHON KOHDEN CORPORATION
13.1.10.1 Business overview
13.1.10.2 Products & services offered
13.1.11 VITALOGRAPH
13.1.11.1 Business overview
13.1.11.2 Products & services offered
13.1.11.3 Recent developments
13.1.11.3.1 Product & service launches & approvals
13.1.11.3.2 Deals
13.1.12 SDI DIAGNOSTICS
13.1.12.1 Business overview
13.1.12.2 Products & services offered
13.1.13 RESMED INC.
13.1.13.1 Business overview
13.1.13.2 Products & services offered
13.1.13.3 Recent developments
13.1.13.3.1 Deals
13.1.13.3.2 Expansions
13.1.13.3.3 Other developments
13.1.14 SIEMENS HEALTHINEERS AG
13.1.14.1 Business overview
13.1.14.2 Products & services offered
13.1.14.3 Recent developments
13.1.14.3.1 Product launches
13.1.14.3.2 Deals
13.1.14.3.3 Expansions
13.1.15 COSMED SRL
13.1.15.1 Business overview
13.1.15.2 Products & services offered
13.1.15.3 Recent developments
13.1.15.3.1 Product launches
13.1.15.3.2 Deals
13.1.16 HOLOGIC, INC.
13.1.16.1 Business overview
13.1.16.2 Products & services offered
13.1.16.3 Recent developments
13.1.16.3.1 Product launches
13.1.16.3.2 Deals
13.1.17 QIAGEN N.V.
13.1.17.1 Business overview
13.1.17.2 Products & services offered
13.1.17.3 Recent developments
13.1.17.3.1 Product launches
13.1.17.3.2 Deals
13.1.17.3.3 Other developments
13.2 OTHER PLAYERS
13.2.1 MGC DIAGNOSTICS CORPORATION
13.2.2 VISBY MEDICAL, INC.
13.2.3 BRIOTA TECHNOLOGIES PVT. LTD.
13.2.4 BIRD HEALTHCARE
13.2.5 LÖWENSTEIN MEDICAL SE & CO. KG
13.2.6 PROAXSIS
13.2.7 NDD MEDICAL TECHNOLOGIES
13.2.8 COMPUMEDICS LIMITED

14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS